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Zusammenfassung
Hintergrund: Wir haben 5 Onkogene, deren Rolle in der 
Karzinogenese etabliert ist (CCND1, ErbB1, ErbB2, c-myc 
und ZNF217), ausgewählt, um die Koexistenz von Ko-
piezahl-Ungleichgewichten in Bezug auf klinisch-patho-
logische Eigenschaften von Ovarialtumoren zu unter-
suchen. Material und Methoden: Zur Detektion dieser 
5 Gene wurde die Fluoreszenz-in-situ-Hybridisierung 
auf ein schon existierendes Gewebe-Microarray ange-
wandt. 38 Ovarialtumoren wurden erfolgreich auf Ver-
änderungen der Kopienzahl dieser 5 Gene untersucht. 
Ergebnisse: Bei 27 von 38 Tumoren (71,1%) war min-
destens eines dieser Onkogene vermehrt/amplifiziert. 
Die höchste Frequenz der genetischen Vermehrung/ 
Amplifikation wurde für c-myc gefunden, da dies für 
42,1% der Ovarialtumore zutraf. Im Falle einer c-myc-
Mutation konnten wir eine sequenzielle Involvierung 
einer Veränderung der Kopienzahl der anderen Gene 
beobachten. Das Auftreten veränderter Kopienzahlen 
der 5 Onkogene – einzeln oder in Kombination – war bei 
Tumoren höheren Grades verstärkt. Alle Doppelaberra-
tionen in der Gruppe der serösen Tumoren umfassten 
Erhöhungen in der Kopienzahl von c-myc und ZNF217. 
Schlussfolgerungen: Unsere Ergebnisse zeigen eine Ver-
knüpfung der Kopienzahlerhöhungen von c-myc und 
ZNF217 sowie eine Assoziation mit seröser Histologie. 
Die Daten aus dieser kombinierten Analyse von 5 Onko-
genen könnten als Basis für die Entwicklung einer kom-
binierten molekularen Therapie bei Ovarialkarzinomen 
verwendet werden.
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Summary
Background: We selected 5 oncogenes with well-estab-
lished roles in carcinogenesis – CCND1, ErbB1, ErbB2, c-
myc and ZNF217 – to investigate the coexistence of their 
copy imbalances in relation to the clinico-pathological 
characteristics of ovarian tumors. Materials and Meth-
ods: Fluorescence in situ hybridization for the 5 genes 
was applied to a preexisting tissue microarray. 38 ovar-
ian tumors were successfully analyzed for copy number 
changes of the 5 genes. Results: At least one of these 
oncogenes was gained/amplified in 27 out of 38 tumors 
(71.1%). We report the highest frequency of c-myc genet-
ic gain/amplification since it affected 42.1% of the ovar-
ian tumors. We observed sequential involvement of copy 
number alterations of the other genes in the presence of 
c-myc disruption. The incidence of copy number chang-
es of the 5 oncogenes – both single and combinatorial – 
was higher in high-grade tumors. All double aberrations 
in the serous group comprised c-myc and ZNF217 copy 
number increases. Conclusions: Our results revealed a 
combination between copy number increases of c-myc 
and ZNF217, associated with serous histology. The data 
from this combined analysis of the 5 oncogenes could be 
used as a basis in considering the combined approach in 















Ovarian carcinoma has the highest mortality of all gyneco-
logical cancers. Close to 75% of the patients have advanced-
stage disease at diagnosis [1]. Their prognosis is correlated 
with numerous clinical and biological factors. The sequential 
transformation of normal epithelium to invasive carcinoma is 
reflected by increasing levels of cellular alterations.
Most ovarian carcinomas show complex chromosome ab-
errations with hypodiploid or near-triploid stem-line copy 
number [2]. The average number of copy alterations index is 
a measure for the number of acquired chromosomal copy al-
terations in a given histological type or at specific stages [3]. 
The accumulated data from ovarian carcinoma suggested the 
presence of at least three modes of karyotypic evolution in this 
tumor type: phase I with 1–7 imbalances (corresponding to 
low stage and grade), phase II with 8–15 imbalances (typical of 
moderate stage and grade), and phase III with > 15 imbalances 
(corresponding to high stage and grade) [4]. Recently, high-
resolution analysis by whole genome arrays revealed > 380 
small regions of copy number gain or loss (< 500 kb) among 31 
primary ovarian cancers; the average number of small-region 
copy imbalances was 12 [5]. Array comparative genomic hy-
bridization (CGH) analysis of 26 ovarian cancers with 1300 ge-
nomic clones identified twice as many imbalances in the group 
of ovarian tumors resistant to standard chemotherapy (55 
losses/gains) compared to the sensitive group (28 losses/gains) 
[6]. In general, the number of chromosomal aberrations clearly 
correlates with disease behavior and progression and seems to 
be a valid marker for increased genomic instability.
It would be exceedingly interesting to analyze if given spe-
cific copy number alterations occur as a sequence and reflect 
a pattern of stage-, grade- or histology-specific parameters.
We selected five oncogenes – CCND1, ErbB1 (EGFR), 
ErbB2 (HER2), c-myc and ZNF217 – for combinatorial fluo-
rescence in situ hybridization (FISH) analysis of their copy 
number changes in a subset of 38 ovarian tumors with differ-
ent histologies, stages and grades. All of them have a well-es-
tablished role in carcinogenesis. CCND1 is a growth-regula-
tory gene; in the G1 phase of the cell cycle, CCND1 together 
with its cyclin-dependent kinase (cdk) partner is responsible 
for the transition to the S phase by phosphorylating the prod-
uct of the retinoblastoma gene (pRb), which then releases 
transcription factors [7]. The HER family members EGFR 
and ErbB2 are receptors of growth factors with an important 
role in normal cell growth and differentiation [8]. c-Myc is a 
transcription activator of proliferation factors and it is also an 
inhibitor of the factors, suppressing growth [9]. ZNF217 en-
codes a Kruppel-like zinc-finger transcription factor and was 
originally identified based on its core location in the 20q13.2 
amplicon observed in some breast and ovarian cancers [10].
The aim of this study was to investigate the coexistence of 
copy imbalances of these oncogenes in relation to the clinico-
pathological characteristics of ovarian tumors.
Materials and Methods
Ovarian Tumor Tissue Microarray
A preexisting tissue microarray (TMA) containing 235 archived ovarian 
tumor samples (from formalin-fixed paraffin-embedded tissue blocks) 
from 235 patients, collected during the period of 1999–2004, was used. 
The ovarian tumors varied considerably in their histological type. The 
TMA contained specimens from all histological variants: serous, muci-
nous, endometrioid, clear cell tumors, Brenner tumors, mixed epithelial 
tumors, undifferentiated, unclassifiable, granulose cell tumors, germline 
cell tumors (teratomas, dysgerminomas). The slides of all tumors were 
reviewed prior to construction by a single pathologist. Tumor stage and 
grade were defined according to Federation of Gynecology and Obstet-
rics (FIGO) and World Health Organization (WHO) criteria [11].
For TMA construction, a hematoxylin and eosin (H&E)-stained section 
was made from each block to define representative tumor areas. Tissue cylin-
ders with a diameter of 0.6 mm were punched from tumor areas and brought 
into a recipient paraffin block using a custom-made precision instrument [12, 
13]. Samples were distributed into two regular-sized recipient paraffin blocks, 
each containing about 500 specimens. 5-Mm sections of the blocks were trans-
ferred to glass slides using a paraffin-sectioning aid system (adhesive coated 
slides, adhesive tape, UV lamp; Instrumedics Inc., Hackensack, NJ, USA).
FISH
Prior to hybridization the slides were treated with the Paraffin Pretreat-
ment Reagent Kit (Vysis). FISH was performed using the following 
probes: HER-2 (erbB2) Spectrum Orange/CEP17 Spectrum Green-labeled 
probe (Cat #30–161060, Vysis), ERBB1 Spectrum Orange/CEP7 Spec-
trum Green-labeled probe (Cat #32–191053, Vysis), Cyclin D1 Spectrum 
Orange/CEP11 Spectrum Green-labeled probe (Cat #32–191039, Vysis), 
c-myc Spectrum Orange (Vysis, Cat #30–190006), ZNF217 Spectrum Or-
ange (Vysis, Cat #32–190016). Denaturation of the DNA was carried out 
at 75 °C for 10 min (probe mixture) or 5 min (slides). The probe mixture 
was applied to the slides and hybridized overnight in a moist chamber at 37 
°C. The posthybridization washes were performed as described in the ‘LSI 
procedure’ (Vysis). Slides were counterstained with DAPI in antifade. The 
presence of > 6 signals (or 3 times more gene signals than centromere sig-
nals per cell) or tight clusters in at least 10% of tumor cells was considered 
as amplification according to the instruction of Vysis (Pathvysion). Pres-
ence of > 2 signals (or more gene signals than centromere signals) in at 
least 10% of tumor cells not reaching the threshold (3 ×) was considered a 
‘gain’. Genetic gain refers to chromosomal aberrations in the cell (numeri-
cal or structural): aneusomies, translocations, duplications, etc.
Statistics
Contingency table analysis and C2 tests were used to study the relationship 
between gene copy number changes and tumor phenotype, i.e. histology, 
tumor grade and stage.
Results
Incidence of Copy Number Changes of the Analyzed Genes
Totally, 38 ovarian cancers were successfully analyzed for 
copy number changes of CCND1, ErbB1, ErbB2, c-myc and 
ZNF217. At least one of these oncogenes was gained/ampli-
fied in 27 out of 38 tumors (71.1%). The copy number changes 
of these oncogenes varied from 0 (in 28.9% of tumors), 1 (in 
39.5%), 2 (in 18.4%), 3 (7.9%) to 4 (in 5.3% of tumors) per 
sample. The type of aberrations, combinations and pathologi-











Single and Combinatorial Gene Alterations
We established copy number increases (both single and com-
bined) of c-myc in 42.1% of ovarian cancers, of ZNF217 in 
39.5%, of ErbB1 in 13.2%, of ErbB2 in 13.2%, and of CCND1 
in 10.5% of the tumors. The most frequent single aberration 
was a gain/amplification of c-myc. It occurred in 6 out of 38 
ovarian tumors (15.8%), followed by ZNF217 (in 13.2%), 
ErbB1 and CCND1 (both in 5.3% of the tumors). None of 
the ovarian tumors had a single aberration of ErbB2. Among 
7 tumors with double aberrations, 5 had combinatorial copy 
number increases of c-myc and ZNF217, 1 had the combi-
nation ErbB1/ErbB2, and 1 had the combination CCND1/
ErbB2. In all 3 tumors with triple aberrations, there was a 
combination of copy increases of c-myc, ZNF217 and ErbB2. 
In 1 of the 2 tumors with 4 aberrations, the copy increases of 
the last three oncogenes were combined with a gain of ErbB1. 
In the second tumor affected by 4 aberrations, the combina-
tion was c-myc/ZNF217/ErbB1/CCND1.
Figure 1 represents the general pattern of sequential in-
volvement of the analyzed genes in ovarian cancers; it exhibits 
the initial involvement of c-myc, followed by co-involvement 
of ZNF217, ErbB2 (HER2), ErbB1 (EGFR) and CCND1, 
consecutively.
Correlation of the Copy Number Increases with the  
Pathological Parameters of the Tumors
We analyzed the incidence of the single and combinatorial 
copy number increases of the oncogenes in ovarian tumors in 
relation to different stages, grades and histology types. The 
results are represented in table 2 for stage, table 3 for grade, 
and table 4 for histology.
There were similar frequencies of the single aberrations in 
the three stages, but the incidence of combined aberrations 
increased with the advance of the stage without reaching 
significance (fig. 2A). The copy number increases of c-myc 
and ZNF217 were present as single aberrations in all groups, 
whereas those of ErbB1 were established only in stage I, and 
those of CCND1 in stage II and III. The ErbB2 copy number 
Histology Grade Stage Aberration (G = gain/A = amplification)
Serous low III ZNF217 (G)
Serous low I c-myc (G) + ZNF217 (G)
Serous low III c-myc (G) + ZNF217 (G)
Serous low I c-myc (G) + ZNF217 (G)  + ErbB2 (G)
Serous low I c-myc (G) + ZNF217 (G) + ERBB1 (G) + CCND1 (A)
Serous high III ZNF217 (G)
Serous high I c-myc (G)
Serous high III c-myc (G)
Serous high I c-myc (A)
Serous high I c-myc (G) + ZNF217 (G)
Serous high III c-myc (G) + ZNF217 (G)
Serous high III c-myc (G) + ZNF217 (G)
Serous high II CCND1 (G) + ErbB2 (G)
Serous high III c-myc (G) + ZNF217 (G) + ErbB2 (G)
Mixed low II ZNF217 (G)
Mixed low II c-myc (A)
Mixed low III c-myc (A)
Endom. low II CCND1 (G)
Clear cell low III c-myc (G) + ZNF217 (G) + ErbB2 (A) + ERBB1 (G)
Mixed high I ERBB1 (A)
Undiff. high III CCND1 (G)
Undiff. high I ZNF217 (G)
Undiff. high III ZNF217 (G)
Undiff. high III c-myc (G)
Endom. high I ERBB1 (G)
Dysgerm. high III ERBB1 (G) + ErbB2 (G)
Undiff. high III c-myc (G) + ZNF217 (G) + ErbB2 (G)
Table 1. Clinico-pathological data and copy 
number changes in ovarian tumors with  
aberrations.
Fig. 1. Sequential involvement of copy number changes of the analyzed 
genes in ovarian tumors: The baseline indicates all ovarian samples; the 
next lines represent respectively single, double, triple and 4 aberrations 
involving c-myc. c-Myc alterations are present here in all aberrant tumors; 











increase appeared as double aberration in 1 tumor from stage 
II and in 1 tumor from stage III. The remaining double aber-
rations comprised the combination c-myc/ZNF217. The latter 
was accompanied by an ErbB2 gain in 1 tumor from stage I 
and in 2 tumors from stage III. An ErbB2 gain was not present 
in stage I tumors affected by 4 aberrations.
The incidence of copy number changes of the five oncogenes – 
both single and combinatorial – was higher in high-grade tumors, 
except for the combination of 4 altered oncogenes (fig. 2B).
There were striking differences in the frequency of single 
aberrations between serous (23.8%) and other ovarian tu-
mors: mixed (80.0%) and non-serous (50.0%). Double aber-
rations occurred 3 times more frequently in serous ovarian 
cancers (fig. 2C). Remarkably, all double aberrations in the 
serous group comprised c-myc and ZNF217 copy number 
increases. The epidermal growth factor receptor ErbB2 and 
ERBB1 increases were combined in the single non-serous 
tumor affected by a double aberration. The unique non-se-
rous tumors with 3 and 4 aberrations were from undifferenti-
ated and clear cell histology, respectively.
Discussion
Genetic pathways defined at the chromosomal level are mir-
rored by genetic changes at the level of the gene. For example, 
p53 mutations are more common in cancer, accompanied by 
the loss of 17p13.1 [13]. The unstable genome is a hallmark fea-
ture of nearly all solid tumors. Cancer is known to be a disease 
of genomic instability with accelerated somatic evolution to a 
genomically heterogeneous population of cells naturally select-
ed for their abilities to proliferate and invade while simultane-
ously evading host defenses. Genomic copy number increases 
are frequently found in cancers and are believed to contribute 
to their development and progression through amplification of 
oncogenes or more subtle gene dosage changes [3].
Here, we have analyzed the coexistence of copy number in-
creases of five oncogenes – CCND1, ErbB1, ErbB2, c-myc and 
ZNF217 – in 38 primary ovarian cancers of different histology, 
stages and grades. The five oncogenes were affected in 71.1% 
of ovarian cancers in single or combined aberrations. It is worth 
to consider their inclusion in a multi-panel for genetic diagnos-
tics of ovarian cancer. Such testing panels exist for urinary blad-
der cancer [14], lung cancer [15], and prostate cancer [16]. The 
remaining 28.9% of the tumors in our set did not harbor altera-
tions in the analyzed genes, but might have gains/amplifications 
in other oncogenes not included in the study. In spite of the 
limited number of samples analyzed in this study, the frequen-
cies of gene alterations are consistent, to a great extent, with 
large-cohort studies like TMA analyses of up to 1000 tumors 
that have been done in our laboratory (data not shown).
We report the highest frequency of c-myc genetic gain/
amplification, since it affected 42.1% of the ovarian tumors. 
Moreover, we observed sequential involvement of copy 
number alterations of the other genes in the presence of c-
myc disruption. Recently, the common fragile site FRA8C 
was cloned and found to map close to the c-myc proto-on-
cogene [17]. According to the genomic database, there were 
at least two more fragile sites in the region, FRA8D (8q24.3) 
and FRA8E (8q24.1). It is well known that fragile sites exhibit 
signs of instability in tumor cells, and they have been impli-
cated in cancer chromosome rearrangements causing deregu-
lation of the genes in the regions [18]. Obviously, c-myc ge-
nomic imbalances, giving rise to the oncogene’s dysfunction, 
Aberrations
Stage None, n (%) Single, n (%) Double, n (%) Triple, n (%) Four, n (%) Total, n
I 4 (30.8) 5 (38.4) 2 (15.4) 1 (7.7) 1 (7.7) 13
II 3 (42.8) 3 (42.8) 1 (14.4) 0 0  7
III 4 (22.2) 7 (38.9) 4 (22.2) 2 (11.1) 1 (5.6) 18
Table 2. The incidence of single and combinato-
rial copy number increases of the oncogenes in 
tumors from different stages
Aberrations
Grade None, n (%) Single, n (%) Double, n (%) Triple, n (%) Four, n (%) Total, n
Low 6 (37.5) 5 (31.2) 2 (12.5) 1 (6.2) 2 (12.5) 16
High 5 (22.7) 10 (45.5) 5 (22.7) 2 (9.1) 0 22
Table 3. The incidence of single and combina-
torial copy number increases of the oncogenes in 
tumors of different grades
Aberrations
Histology None, n (%) Single, n (%) Double, n (%) Triple, n (%) Four, n (%) Total, n
Serous 7 (33.3) 5 (23.8) 6 (28.6) 2 (9.5) 1 (4.8) 21
Mixed 1 (20.0) 4 (80.0) 0 0 0 5
Non-serous 3 (25.0) 6 (50.0) 1 (8.3) 1 (8.3) 1 (8.3) 12
Table 4. The incidence of single and combina-
torial copy number increases of the oncogenes in 











Another frequent combined alteration was found between 
erbB-1 and erbB-2, being used as an independent prognostic 
factor for specific survival [23, 24]. According to others, there 
are no combined alterations of erbB-1 and erbB-2 [25], or the 
changes of erbB-1 are commonly accompanied by those of 
erbB-3 [26]. Ambiguous data were reported for CCND1; its 
amplification is correlated to 20q13.2 amplification according 
to some authors [27] or the two genes were affected independ-
ently according to others [28, 29].
We were interested in verifying whether some of the 
anomalies we had analyzed were diagnostic in terms of sepa-
rating tumors of different stage, grade or histological types. 
We discovered that c-myc and ZNF217 were altered in all 
stages, whereas ErbB2 was altered mainly in advanced stages. 
Moreover, ErbB2 copy number increases were not detected as 
single aberrations in ovarian tumors in our study. The combi-
nation between amplification of c-myc and ErbB2 was found 
to be associated with poor patient survival and was suggested 
to be a worse prognostic indicator of ovarian cancer develop-
ment in another study [30].
High-grade ovarian tumors were associated with a higher 
incidence of copy number alterations in our study. Assessing 
the DNA copy number changes in 33 high-grade serous car-
cinomas and 10 low-grade serous tumors by using a genome-
wide technique, a single-nucleotide polymorphism array, Na-
kayama et al. found that high-grade serous carcinomas showed 
widespread DNA copy number changes in comparison to low-
grade tumors [31]. It is evident that the poorly differentiated 
tumors are genetically more instable.
Combined copy number increases of c-myc and ZNF217 
(20q13) were consistently observed in ovarian serous cancers 
in our study and were not detected in the non-serous histolog-
ical type. This coexistence does not seem to be occasional, but 
a fact that indicates a strong correlation between mutations 
of the two genes. Yang and colleagues suggested that the key 
gene of the 20q13.2 amplicon STK15 activates human telom-
erase reverse transcriptase (hTERT) by targeting the c-myc 
transcription factor [32]. We suggest that the copy numbers 
of the two genes are very often increased together, especially 
in serous ovarian cancers; probably, this is one of the possible 
mechanisms for dysregulation of this pathway.
In conclusion, our results revealed a combination between 
copy number increases of c-myc and ZNF217, associated with 
serous histology. Genomic imbalances of c-myc are early 
events in ovarian tumorigenesis, and those of ErbB2, ErbB1 
and ZNF217 (20q13.2) are late events. The data from this 
combined analysis of the five oncogenes could be used as a 
basis for considering a combined approach in molecular-based 
therapy of ovarian cancer.
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Fig. 2. The incidence of copy number increases of the analyzed genes in 
relation to clinico-pathological parameters: (A) tumor stage, (B) tumor 
grade, (C) histology.
emerged as an early event in ovarian carcinogenesis, due to 
the common instable site in the 8q24 locus. It was followed by 
copy number changes in the other potential oncogenes ana-
lyzed in our study – ZNF217, ErbB2, ErbB1 and CCND1. A 
similar pattern of sequence was discovered in breast cancer 
progression, where c-myc amplification was an early event 
while ZNF217 and ErbB2/neu amplifications were suggested 
to play a role in the later stage of tumor development [19]. 
The copy numbers of ErbB2, ErbB1 and ZNF217 were al-
tered more often together with other genes in our study, 
a fact supporting the idea of their later involvement in the 
process of ovarian carcinogenesis. There are reports of com-
bined aberrations of HER receptor genes and c-Myc, which is 
their potential effector [20, 21], and even combined anti-gene 
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